1.Dent, R, Trudeau, M, Pritchard, K Iet al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429–4434.
2.Kreike, B, Van Kouwenhove, M, Horlings, Het al. Gene expression profiling and histopathological characterization of triple-negative/basallike breast carcinomas. Breast Cancer Res 2007; 9: R65.
3.Livasy, C A, Karaca, C, Nanda, Ret al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264–271.
4.Foulkes, W D, Smith, I E, Reis-Filho, J S. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938–1948.
5.Cleator, S, Heller, W, Coombes, R C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235–244.
6.Irwin, W J Jr, Carey, L A. What is triple negative breast cancer. Eur J Vancer 2008; 44: 2799–2805.
7.Stockmans, G, Deraedt, K, Wildiers, Het al. Triple negative breast cancer. Curr Opin.Oncol. 2008; 20: 614–620.
8.Reis-Filho, J S, Tutt, A N. Triple negative tumours: a critical review. Histopathology 2008; 52: 108–118.
9.Diaz, L K, Cryns, V L, Symmans, F, Sneige, N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419–430.
10.Perou, C M, Sørlie, T, Eisen, M Bet al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747–752.
11.Patil, V W, Singhai, R, Patil, A Vet al. Triple-negative (ER, PgR, HER 2/neu) breast cancer in Indian women. Breast Cancer: Targets and Therapy 2011; 3: 9–19.
12.Longacre, T A, Bartow, S A. A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986; 10: 382.
13.Rodriguez-Pinilla, S M, Sarrio, D, Honrado, Eet al. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clin Cancer Res 2006; 12: 1533–1539.
14.Liedtke, C, Mazouni, C, Hess, K Ret al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275–1281.
15.Hayes, D F, Thor, A D, Dressler, L Get al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357: 1496–1506.
16.Kassam, F, Enright, K, Dent, Ret al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009; 9: 29–33.
17.Roche, H, Li, R, Ro, Jet al. Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials. Poster presentation at the San Antonio Breast Cancer Symposium (SABCS), 10–14 Dec 2008 (Abstr 2015), San Antonio, TX.
18.Farmer, H, McCabe, N, Lord, C Jet al. Targeting the DNA repair defect in BRCA1 mutant cells as a therapeutic strategy. Nature 2005; 434: 917–921.
19.Garber, J F, Richardson, A, Harris, L N. Neo-adjuvant cisplatin (CDDP) in ‘triple negative’ breast cancer (BC) [abstract 308]. Breast Cancer Res Treat 2006; 100 (suppl 1, Abstract 308 S32.
20.Duffy, M J, Duggan, C, Keane, Ret al. High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer. Clin Chem 2004; 50: 3559–3563.
21.Taha, F M, Zeeneldin, A A, Amani, Met al. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem 2009; 42: 1420–1426.
22.Khafagy, W, Aref, S, Zalata, K. Association of serum vascular endothelial growth factor level with estrogen receptors status in breast cancer patients. Egypt J Surg 2005; 24 (4): 188–194.
23.Heer, K, Kumar, H, Speirs, Vet al. Preoperative serum VEGF in primary breast cancer patients – its relation with oestrogen receptor status and cancer type. Eur J Cancer 1998; 34 (5): S29.
24.Derya, D, Hakan, C, Hilal, S O, Duygu, D, Vidan, Y. Serum levels of angiogenic factors in early breast cancer remain close to normal. The Breast 2009; 18: 26–29.
25.Linderholm, B K, Helborg, H, Johansson, Uet al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol 2009; 20: 1639–1646.
26.Verheul, H M, Pinedo, H M. The importance of platelet counts and their contents in cancer. Clin Cancer Res 2003; 7: 3219–3221.
27.Wynendaele, W, Derua, R, Hoylaerts, M Fet al. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol 1999; 10: 965–971.
28.Lee, J K, Hong, Y J, Han, C Jet al. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol 2000; 17: 149–152.
29.Park, B W, Oh, J W, Kim, J Het al. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 2008; 19: 675–681.
30.Martin, A, Corte, D, Alvarez, A Met al. Prognostic value of pre-operative serum CA 15.3 levels in breast cancer. Anticancer Res 2006; 26: 3965–3972.
31.Velaiutham, S, Taib, N A, Ng, K L, Yoong, B K, Yip, C H. Does the pre-operative value of serum CA15-3 correlate with survival in breast cancer? Asian Pac J Cancer Prev 2008; 9: 445–448.
32.Agrawal, A K, Jelen, M, Rudnicki, Jet al. The importance of preoperative elevated serum levels of CEA and CA15-3 in patients with breast cancer in predicting its histological type. Folia Histochemica et Cytobiologica 2010; 48 (1): 26–29.
33.Berruti, A, Tampelllini, M, Torta, Met al. Prognostic value in predicting overall survival of two mucinous markers; CA 15.3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 2082–2084.
34.Laessig, D, Nagel, D, Heinemann, Vet al. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 2007; 27: 1963–1968.
35.Ferrero, S, Nicoletti, A, Ragni, N. Letter to the editor: measurement of serum vascular endothelial growth factor in breast cancer patients. Intern Med J 2005; 35: 310–314.
36.Inai, T, Mancuso, M, Hashizume, Het al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165: 35–52.
37.Jain, R K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.
38.Diaz, L K, Cryns, V L, Symmans, F, Sneige, N. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 2007; 14: 419–430.
39.Miller, K, Wang, M, Gralow, Jet al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–2676.